

UK Cardiovascular Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Observational), By Indication (Stroke, Cardiac Arrhythmias, Heart Failure), And Segment Forecasts, 2026 - 2033

<https://marketpublishers.com/r/U8BD8BDE6654EN.html>

Date: April 2026

Pages: 140

Price: US\$ 5,950.00 (Single User License)

ID: U8BD8BDE6654EN

Abstracts

The UK cardiovascular clinical trials market size was estimated at USD 507.8 million in 2025 and is projected to reach USD 892.2 million by 2033, growing at a CAGR of 7.6% from 2026 to 2033. The market growth is driven by integrated healthcare data access, strong research funding, and regulatory acceleration.

In the country, the integrated infrastructure of the National Health Service (NHS) enables access to ~67 million patient records, which is expected to drive the recruitment and real-world evidence generation for cardiovascular clinical trials. In addition, the growing prevalence of cardiovascular disease (~7.6 million patients) has driven an increase in clinical trials, further contributing to market growth.

The UK cardiovascular clinical trials industry is growing due to rising cardiovascular disease burden in the country, regulatory acceleration and adaptive trial frameworks in the UK, and increasing investment in cardiovascular drugs innovation and late-stage pipelines. Due to the rising incidence of cardiovascular disease across the UK, there is continued demand for long-term, large-scale clinical trials. Cardiovascular conditions like heart failure, coronary heart disease (CHD), atrial fibrillation, and ischemic heart disease require ongoing innovations in medications and treatment. This is mainly responsible for the growing number of clinical trials in the country, as these trials are usually conducted using evidence from real-world experiences from NHS databases.

The data published by the British Heart Foundation (BHF) in January 2026 stated that nearly 7 million people currently live with cardiovascular disease in England. The growing and aging population is further expected to boost the rate of CVDs, owing to improved survival rates from cardiovascular events. As the risk of CVD increases with age, by 2030, the population in England aged 65-84 is anticipated to increase by 29% and those aged over 85 by 61%. Furthermore, CVDs are also responsible for ~26% (140,000) of the total deaths in the country per year, which equates to 380 people per day. Amongst which, 38,000 people die under the age of 75 in England each year. Such a growing burden of CVDs in the country has increased the demand for new interventions and treatments, as the government and the public health authorities-led efforts aimed at reducing deaths from cardiovascular disease are providing a steady stream of financial support to clinical studies in the country. In addition, the demand for preventive cardiology therapies is increasing the clinical trial pipeline for cholesterol-lowering drugs and hypertension medications. All these factors contribute to market growth.

Furthermore, the growing investment in drugs for cardiometabolic diseases is boosting the pipeline of cardiovascular clinical trials in the UK, as pharmaceutical companies develop treatments for lipid disorders, heart failure, and inflammation. Besides, large-scale late-phase clinical trials are underway in various parts of the world, involving more than 10,000 participants, which is driving greater demand for UK-based clinical trial sites due to their specialized facilities. Moreover, research into new modes of action, such as inhibiting PCSK9 with RNA-based drugs and anti-inflammatories, is generating interest in early- and mid-phase clinical trials. Also, cooperation between international sponsors and domestic research networks is speeding up site activation and the patient enrollment process. Besides, there is intense competition among companies to demonstrate better cardiovascular outcomes, leading to a higher number of trials involving comparative and combination studies. Furthermore, regulatory pressure for the new drug discovery process is driving a rapid transition from Phase II to Phase III clinical trials.

In addition, government support, both public and private, is helping translational research progress to clinical phase trials. For example, in January 2026, Novo Nordisk announced the extension of its cardiovascular outcome studies in the UK, following increased clinical focus on reducing obesity-related cardiovascular risks. Thus, such an increase in the growing number of investments in the field of cardiology and late-stage pipelines is anticipated to propel the market growth.

UK Cardiovascular Clinical Trials Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the UK cardiovascular clinical trials market report based on phase, study design, and indication:

Phase Outlook (Revenue, USD Million, 2021 - 2033)

Phase I

Phase II

Phase III

Phase IV

Study Design Outlook (Revenue, USD Million, 2021 - 2033)

Interventional

Observational

Expanded Access

Indication Outlook (Revenue, USD Million, 2021 - 2033)

Valvular Heart Disease

Peripheral Artery Disease

Ischemic Heart Disease

Pulmonary Arterial Hypertension

Stroke

Cardiac Arrhythmias

Heart Failure

Other Indications

Contents

CHAPTER 1. METHODOLOGY AND SCOPE

- 1.1. Market Segmentation and Scope
- 1.2. Segment Definitions
 - 1.2.1. Phase
 - 1.2.2. Study Design
 - 1.2.3. Indication
- 1.3. Research Methodology
- 1.4. Information Procurement
 - 1.4.1. Purchased Database
 - 1.4.2. GVR's Internal Database
 - 1.4.3. Secondary Sources
 - 1.4.4. Primary Research
- 1.5. Information Or Data Analysis
 - 1.5.1. Data Analysis Models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
 - 1.7.1. Commodity Flow Analysis
 - 1.7.2. Top-Down Analysis
 - 1.7.3. Bottom-Up Approach
 - 1.7.4. Multivariate Analysis
- 1.8. List of Secondary Sources
- 1.9. List of Abbreviations
- 1.10. Objectives

CHAPTER 2. EXECUTIVE SUMMARY

- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights

CHAPTER 3. UK CARDIOVASCULAR CLINICAL TRIALS MARKET VARIABLES, TRENDS, & SCOPE

- 3.1. Market Lineage Outlook
 - 3.1.1. Parent Market Outlook
 - 3.1.2. Ancillary Market Outlook

3.2. Market Dynamics

3.2.1. Market Driver Analysis

3.2.1.1. Rising Cardiovascular Disease Burden in the Country

3.2.1.2. Regulatory Acceleration and Adaptive Trial Frameworks in the UK

3.2.1.3. Increasing Investment in Cardiometabolic Innovation and Late-Stage

Pipelines

3.2.2. Market Restraint Analysis

3.2.2.1. Limited Site Capacity and Complex Trial Execution

3.2.3. Market Opportunity Analysis

3.2.4. Market Challenge Analysis

3.3. R&D Investment & Funding Analysis

3.4. Pricing Model Analysis

3.5. Regulatory Landscape

3.6. Technology Landscape

3.7. Clinical Trial Design Analysis

3.8. Industry Ecosystem Analysis

3.8.1. Demand Analysis

3.8.2. Supply Chain Analysis

3.9. Clinical Trials Volume Analysis, 2025

3.10. Market Analysis Tools

3.10.1. Porter's Five Force Analysis

3.10.2. PESTEL by SWOT Analysis

CHAPTER 4. UK CARDIOVASCULAR CLINICAL TRIALS MARKET: PHASE ESTIMATES & TREND ANALYSIS

4.1. UK Cardiovascular Clinical Trials Market Segment Dashboard

4.2. UK Cardiovascular Clinical Trials Market: Phase Movement Analysis

4.3. UK Cardiovascular Clinical Trials Market Size & Trend Analysis, by Phase, 2021 to 2033 (USD Million)

4.4. Phase I

4.4.1. Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)

4.5. Phase II

4.5.1. Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)

4.6. Phase III

4.6.1. Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)

4.7. Phase IV

4.7.1. Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)

CHAPTER 5. UK CARDIOVASCULAR CLINICAL TRIALS MARKET: STUDY DESIGN ESTIMATES & TREND ANALYSIS

- 5.1. UK Cardiovascular Clinical Trials Market: Segment Dashboard
- 5.2. UK Cardiovascular Clinical Trials Market: Study Design Movement Analysis
- 5.3. UK Cardiovascular Clinical Trials Market Size & Trend Analysis, by Study Design, 2021 to 2033 (USD Million)
- 5.4. Interventional
 - 5.4.1. Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.5. Observational
 - 5.5.1. Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.6. Expanded Access
 - 5.6.1. Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)

CHAPTER 6. UK CARDIOVASCULAR CLINICAL TRIALS MARKET: INDICATION ESTIMATES & TREND ANALYSIS

- 6.1. UK Cardiovascular Clinical Trials Market: Segment Dashboard
- 6.2. UK Cardiovascular Clinical Trials Market: Indication Movement Analysis
- 6.3. UK Cardiovascular Clinical Trials Market Size & Trend Analysis, by Indication, 2021 to 2033 (USD Million)
- 6.4. Valvular Heart Disease
 - 6.4.1. Valvular Heart Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5. Peripheral Artery Disease
 - 6.5.1. Peripheral Artery Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6. Ischemic Heart Disease
 - 6.6.1. Ischemic Heart Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.7. Pulmonary Arterial Hypertension
 - 6.7.1. Pulmonary Arterial Hypertension Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.8. Stroke
 - 6.8.1. Stroke Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.9. Cardiac Arrhythmias
 - 6.9.1. Cardiac Arrhythmias Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.10. Heart Failure

6.10.1. Heart Failure Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.11. Other Indications

6.11.1. Other Indications Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)

CHAPTER 7. COMPETITIVE LANDSCAPE

7.1. Key Participant Categorization

7.1.1. Market Leaders

7.1.2. Emerging Players

7.2. Market Assessment Analysis, 2025 (Heat Map Analysis)

7.3. Company Profiles

7.3.1. IQVIA Inc.

7.3.1.1. Company Overview

7.3.1.2. Financial Performance

7.3.1.3. Product/Service Benchmarking

7.3.1.4. Strategic Initiatives

7.3.2. ICON plc

7.3.2.1. Company Overview

7.3.2.2. Financial Performance

7.3.2.3. Product/Service Benchmarking

7.3.2.4. Strategic Initiatives

7.3.3. Parexel International (MA) Corporation

7.3.3.1. Company Overview

7.3.3.2. Financial Performance

7.3.3.3. Product/Service Benchmarking

7.3.3.4. Strategic Initiatives

7.3.4. Medpace Holdings, Inc.

7.3.4.1. Company Overview

7.3.4.2. Financial Performance

7.3.4.3. Product/Service Benchmarking

7.3.4.4. Strategic Initiatives

7.3.5. Charles River Laboratories

7.3.5.1. Company Overview

7.3.5.2. Financial Performance

7.3.5.3. Product/Service Benchmarking

7.3.5.4. Strategic Initiatives

7.3.6. MAC Research

7.3.6.1. Company Overview

- 7.3.6.2. Financial Performance
- 7.3.6.3. Product/Service Benchmarking
- 7.3.6.4. Strategic Initiatives
- 7.3.7. Sofpromed
 - 7.3.7.1. Company Overview
 - 7.3.7.2. Financial Performance
 - 7.3.7.3. Product/Service Benchmarking
 - 7.3.7.4. Strategic Initiatives
- 7.3.8. Syneos Health
 - 7.3.8.1. Company Overview
 - 7.3.8.2. Financial Performance
 - 7.3.8.3. Product/Service Benchmarking
 - 7.3.8.4. Strategic Initiatives
- 7.3.9. Worldwide Clinical Trials
 - 7.3.9.1. Company Overview
 - 7.3.9.2. Financial Performance
 - 7.3.9.3. Product/Service Benchmarking
 - 7.3.9.4. Strategic Initiatives
- 7.3.10. Laboratory Drug Development
 - 7.3.10.1. Company Overview
 - 7.3.10.2. Financial Performance
 - 7.3.10.3. Product/Service Benchmarking
 - 7.3.10.4. Strategic Initiatives
- 7.3.11. AstraZeneca
 - 7.3.11.1. Company Overview
 - 7.3.11.2. Financial Performance
 - 7.3.11.3. Product/Service Benchmarking
 - 7.3.11.4. Strategic Initiatives
- 7.3.12. Novartis
 - 7.3.12.1. Company Overview
 - 7.3.12.2. Financial Performance
 - 7.3.12.3. Product/Service Benchmarking
 - 7.3.12.4. Strategic Initiatives
- 7.3.13. Pfizer
 - 7.3.13.1. Company Overview
 - 7.3.13.2. Financial Performance
 - 7.3.13.3. Product/Service Benchmarking
 - 7.3.13.4. Strategic Initiatives
- 7.3.14. Bristol Myers Squibb

- 7.3.14.1. Company Overview
- 7.3.14.2. Financial Performance
- 7.3.14.3. Product/Service Benchmarking
- 7.3.14.4. Strategic Initiatives
- 7.3.15. Johnson & Johnson
 - 7.3.15.1. Company Overview
 - 7.3.15.2. Financial Performance
 - 7.3.15.3. Product/Service Benchmarking
 - 7.3.15.4. Strategic Initiatives

List Of Tables

LIST OF TABLES

Table 1. List of Secondary Sources

Table 2. List of Abbreviations

Table 3. UK Cardiovascular Clinical Trials Market Estimates and Forecasts, by Phase, 2021 - 2033 (USD Million)

Table 4. UK Cardiovascular Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)

Table 5. UK Cardiovascular Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)

List Of Figures

LIST OF FIGURES

- Fig. 1 Market research process
- Fig. 2 Information procurement
- Fig. 3 Primary research pattern
- Fig. 4 Market research approaches
- Fig. 5 Market formulation & validation
- Fig. 6 Commodity flow analysis
- Fig. 7 Value-chain-based sizing & forecasting
- Fig. 8 QFD model sizing & forecasting
- Fig. 9 Bottom-up approach
- Fig. 10 Market snapshot
- Fig. 11 Segment snapshot 1
- Fig. 12 Segment snapshot 2
- Fig. 13 Competitive landscape snapshot
- Fig. 14 Parent market outlook, 2025 (USD Million)
- Fig. 15 Ancillary market outlook, 2025 (USD Million)
- Fig. 16 UK Cardiovascular Clinical Trials Market Dynamics
- Fig. 17 Porter's five forces analysis
- Fig. 18 PESTEL analysis
- Fig. 19 UK Cardiovascular Clinical Trials Market: Phase Outlook And Key Takeaways
- Fig. 20 UK Cardiovascular Clinical Trials Market: Phase Movement Analysis
- Fig. 21 Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Fig. 22 Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Fig. 23 Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Fig. 24 Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Fig. 25 UK Cardiovascular Clinical Trials Market: Study Design Outlook And Key Takeaways
- Fig. 26 UK Cardiovascular Clinical Trials Market: Study Design Movement Analysis
- Fig. 27 Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Fig. 28 Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Fig. 29 Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Fig. 30 UK Cardiovascular Clinical Trials Market: Indication Outlook And Key Takeaways
- Fig. 31 UK Cardiovascular Clinical Trials Market: Indication Movement Analysis
- Fig. 32 Valvular Heart Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 33 Peripheral Artery Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 34 Ischemic Heart Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 35 Pulmonary Arterial Hypertension Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 36 Stroke Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 37 Cardiac Arrhythmias Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 38 Heart Failure Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 39 Other Indications Market Estimates and Forecasts, 2021 - 2033 (USD Million)

I would like to order

Product name: UK Cardiovascular Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design Interventional, Observational), By Indication (Stroke, Cardiac Arrhythmias, Heart Failure), And Segment Forecasts, 2026 - 2033

Product link: <https://marketpublishers.com/r/U8BD8BDE6654EN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U8BD8BDE6654EN.html>